When.com Web Search

  1. Ads

    related to: new treatments for amd eyes pictures and benefits

Search results

  1. Results From The WOW.Com Content Network
  2. Stem cell therapy for macular degeneration - Wikipedia

    en.wikipedia.org/wiki/Stem_cell_therapy_for...

    Induced pluripotent stem cell taken from blood cell and converted in retinal pigment epithelium. Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD). [1]

  3. Intravitreal injection - Wikipedia

    en.wikipedia.org/wiki/Intravitreal_injection

    Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. [1] It is used to treat various eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye such as endophthalmitis. [1]

  4. Geographic atrophy - Wikipedia

    en.wikipedia.org/wiki/Geographic_atrophy

    Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of central vision over time.

  5. Macular degeneration - Wikipedia

    en.wikipedia.org/wiki/Macular_degeneration

    In advanced stages of AMD, atrophy of the RPE (geographic atrophy) and/or development of new blood vessels (neovascularization) result in the death of photoreceptors and central vision loss. [citation needed] In the dry (nonexudative) form, drusen accumulates between the retina and the choroid, causing atrophy and scarring to the retina. In the ...

  6. Ranibizumab - Wikipedia

    en.wikipedia.org/wiki/Ranibizumab

    Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

  7. National Eye Institute - Wikipedia

    en.wikipedia.org/wiki/National_Eye_Institute

    Comparison of Age-Related Macular Degeneration Treatments Trial: Lucentis-Avastin Trial: This two-year, multicenter clinical trial compared the effectiveness of two treatments used for AMD: Lucentis and Avastin. It showed that both treatments are equally effective in treating AMD and improving vision, whether used monthly or as needed. [11] [12]